- ENA Respiratory dosed first participants in a Phase II study (announced Mar 2026) of INNA-051, a once-weekly nasal spray evaluating safety, tolerability and potential effectiveness in adults at increased exposure risk.
- Aptar Pharma's Unidose (UDS) Powder Nasal Spray System delivers single, precise dry-powder doses for clinical administration.
- Aptar CSP Technologies' container closure features 3-Phase Activ-Polymer moisture protection and internal safeguards to prevent premature actuation.
Phase II study update
ENA Respiratory has dosed the first participants in a Phase II, community‑based study of INNA‑051, a once‑weekly nasal spray being evaluated for safety, tolerability and potential effectiveness in adults at increased risk of exposure to viral respiratory infections; the study is designed to assess the agent’s potential to reduce symptomatic respiratory viral illness.
Delivery system
Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System is being used in the study to deliver single, precise dry‑powder doses with consistent intranasal performance and a ready‑to‑use design intended for clinical administration and formulations that may benefit from enhanced stability.
Container closure and device safety
The nasal delivery system is housed in Aptar CSP Technologies’ container closure incorporating fully‑integrated 3‑Phase Activ‑Polymer technology to protect powder against moisture; internal features are designed to prevent premature actuation from insertion, removal or dropping, supporting reliable patient access to the dose.
